HDO Free Trial & Collaborative Research Call 2026
Evaluate HDO for your target in your own in vivo model.
Rena Therapeutics Inc. invites researchers from universities, research institutions, pharmaceutical companies, biotechnology companies, and other organizations to submit research proposals for the HDO Free Trial & Collaborative Research Call 2026.
The program consists of two tracks: Program A, an HDO Free Trial Program for researchers who already have a validated ASO sequence, and Program B, a Strategic Area Collaborative Research Program limited to three designated research areas.
By combining researchers’ targets and in vivo models with HDO technology, we aim to explore new therapeutic approaches and potential drug discovery opportunities.
Application Period
October 1-31, 2026
Expected Number of Selected Projects
Four projects in total: Program A: 3 / Program B: 1
Review and Selection
All applications received during the application period will be reviewed after the application deadline, and selected projects will be determined promptly thereafter.
Applications will not be selected on a rolling or first-come, first-served basis.
Eligibility
Researchers affiliated with universities, research institutions, companies, or other eligible organizations who can conduct studies using their own in vivo experimental systems.
Important: Submit Non-Confidential Information Only
All applications must be submitted on a non-confidential basis.
Please do not include any confidential, proprietary, or unpublished detailed technical information in the online application, Research Proposal Form, or supporting materials.
In particular, please do not submit:
- Specific ASO or other oligonucleotide sequences
- Detailed unpublished chemical structures
- Specific details of unfiled inventions
- Information subject to third-party confidentiality obligations
- Any other information managed as confidential by the applicant or the applicant’s institution
At the application stage, please describe the research theme, disease area, target, research objective, in vivo model, and validation status only to the extent that no confidential information is disclosed.
If confidential information is required for further evaluation of a selected or shortlisted proposal, such information may be exchanged separately after appropriate confidentiality arrangements are put in place.
Information submitted through the application form is not accepted on the assumption that it will be treated as confidential. Do not submit confidential information.
HDO Technology and Licensing
HDO (Heteroduplex Oligonucleotide) is an oligonucleotide technology consisting of an antisense oligonucleotide and its complementary strand.
Rena Therapeutics Inc. holds an exclusive license from Institute of Science Tokyo (formerly Tokyo Medical and Dental University) to foundational patents relating to HDO technology.
For the sale of HDO research reagents, Rena Therapeutics has granted sublicenses to Nippon Gene Co., Ltd. and NIPPON SHOKUBAI CO., LTD.
This call is intended to explore new applications of HDO technology across a broad range of research themes and disease areas.
Program A: HDO Free Trial Program
Eligible applicants: Researchers who already have a validated ASO sequence. Disease areas are not restricted in principle.
Projects outside the three designated areas for Program B are, in principle, encouraged to apply to Program A if the applicant has a validated ASO sequence.
- Free HDO for in vivo evaluation
- Up to 15 mg of HDO
- Standard ligand-modified HDO (e.g., Toc-modified) or unmodified HDO
- Expected selection: 3 projects
Manufacturing timeline: Approximately 4-6 weeks after selection and confirmation of the required information and sequence.
Intellectual property: Results generated by the applicant will, in principle, belong to the applicant. Rena Therapeutics will have a six-month priority negotiation right regarding the results.
Research report: An evaluation report is expected within approximately six months after receipt of HDO. Research results may be introduced as a use case on the Rena Therapeutics website or other communications after publication or after an agreed period, following discussion with the applicant.
Program B: Strategic Area Collaborative Research Program
Program B is limited to research projects in the following three areas:
- Kidney
- Hematology & Immunology
- Neuromuscular Diseases
Projects outside these three areas are, in principle, not eligible for Program B. Researchers with a validated ASO sequence are encouraged to consider Program A.
- Free HDO for in vivo evaluation
- Collaborative research funding : Up to JPY 3 million (determined based on research duration and scope)
- Expected selection : 1 project
Manufacturing timeline : Approximately 4-6 weeks after execution of the collaborative research agreement and confirmation of the required information and sequence.
Intellectual property : Results generated through the collaborative research will, in principle, be treated as jointly generated results, with joint patent filing contemplated. Details will be governed by the collaborative research agreement.
Research reporting and handling of results will be governed by the collaborative research agreement.
Which Program Should I Apply To?
Is your research theme in Kidney, Hematology & Immunology, or Neuromuscular Diseases?
- Yes: If you are seeking a collaborative research project, consider Program B. Program A may also be available if you only wish to evaluate HDO and meet the Program A requirements.
- No: If you have a validated ASO sequence, please consider Program A.
Please refer to the full application guidelines for final eligibility requirements.
Application Process
STEP 1 Online Application
Complete the online application form and upload a Research Proposal Form containing non-confidential information only.
STEP 2 Application Deadline
October 31, 2026. No rolling or first-come, first-served selection will be made.
STEP 3 Review and Selection
After the application period closes, all submitted themes will be reviewed and selected projects will be determined promptly.
STEP 4 Notification
All applicants will be notified of the selection result.
STEP 5 Detailed Discussion
For selected projects, information required for HDO design, manufacturing, and research planning will be confirmed. Where confidential information is required, it may be exchanged after appropriate confidentiality arrangements are put in place. Program B projects will proceed after execution of a collaborative research agreement.
STEP 6 HDO Manufacturing and Delivery
HDO will be manufactured and delivered after the required conditions and sequence information have been confirmed.
Application Information
Application Period: October 1-31, 2026
Review Timing: After the application period closes
Expected Selection: Program A: 3 projects / Program B: 1 project
Eligible Applicants: Researchers at universities, research institutions, companies, and other eligible organizations
Required Capability: Ability to conduct the proposed study using the applicant’s own in vivo experimental system
Application Method: Online application through this website
Application Language: Japanese or English
Application Fee: None
Information Handling: Non-confidential basis only. Do not submit confidential information in the application form, Research Proposal Form, or supporting materials.
Benefit for Applicants Not Selected
Applicants whose proposals are not selected are expected to receive a 20% discount coupon for contract oligonucleotide synthesis.
Coupon validity: through March 31, 2027
Further details will be provided together with the selection result.
Important Notice
- HDO supplied under this program is for research use only and must not be used for clinical purposes.
- Additional information may be requested during the review process.
Conditions will be specified in a Material Transfer Agreement (MTA). - Do not submit confidential information at the application stage.
- For Program B, commencement of collaborative research will be subject to execution of a collaborative research agreement.
Collaboration Partners
- Nippon Gene Co., Ltd.
- FUJIFILM Wako Pure Chemical Corporation
- NIPPON SHOKUBAI CO., LTD.
(Note: This call is organized and managed solely by Rena Therapeutics Inc. Collaboration partners are not involved in the review process, and submitted application information will not be disclosed to them.)
Contact
Rena Therapeutics Inc.
HDO Free Trial & Collaborative Research Call Office
E-mail: i.nozawa@renatherapeutics.com